MBX Biosciences CEO Steps Down; Executive Chairman Steven Hoerter Takes the Helm as New CEO
MBX has more than doubled off its 52-week low of $9.63.
Summary
Effective July 13, 2026, MBX Biosciences CEO Kent Hawryluk steps down, with Executive Chairman Steven Hoerter becoming President and CEO and interim CFO John Smither appointed permanent CFO. The transition includes new employment agreements and equity grants for the incoming executives.
Key Events · Executive and Board Changes · MBX
-
CEO Departure
Effective July 13, 2026, CEO and co-founder Kent Hawryluk steps down, with severance that includes 12 months' base salary, target bonus, COBRA, and accelerated vesting of equity awards through August 16, 2027.
-
New CEO Appointment
Executive Chairman Steven Hoerter becomes President and CEO on July 13, 2026, with a $665,000 base salary, 60% target bonus, and equity grants of 331,000 options and 71,000 RSUs vesting over four years.
-
CFO Appointment
Interim CFO John Smither is appointed permanent CFO effective July 13, 2026, with a $530,000 base salary, 40% target bonus, $150,000 relocation bonus, and equity grants of 130,000 options and 28,000 RSUs.
-
No Dispute
The filing states Hawryluk's departure is not due to any dispute or disagreement with the company or its auditors.
Analysis · MBX · Life Sciences
MBX Biosciences announced an immediate leadership transition: CEO and co-founder Kent Hawryluk is stepping down, and Executive Chairman Steven Hoerter has been appointed President and CEO. The change is not due to any dispute. Hawryluk will receive severance including 12 months' salary, target bonus, and accelerated equity vesting through August 2027. Hoerter's compensation includes a $665,000 base salary, 60% target bonus, and equity grants of 331,000 options and 71,000 RSUs. Interim CFO John Smither was also made permanent CFO with a $530,000 salary, 40% bonus, and equity grants. The sudden CEO departure at a clinical-stage biotech with recent positive data raises questions about strategic direction, though the appointment of an experienced insider as successor may provide continuity.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBX was trading at $54.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $9.63 to $66.55. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.